prednisolone and Facial Neoplasms studies

Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.

Research Excerpts

Excerpt	Relevance	Reference
" A cavernous hemangioma was suspected and treated with high doses of propranolol and prednisolone."	7.85	Unexpected Effect of Propranolol and Prednisolone on Infantile Facial Rhabdomyosarcoma. ( Bhandari, SB; Lemperle, G; Mentzel, T; Shakya, J; Shilpakar, R, 2017)
"The study comprised 25 consecutive patients with infantile hemangioma managed with oral prednisolone between 2007 and 2010."	7.77	Oral prednisolone for infantile hemangioma: efficacy and safety using a standardized treatment protocol. ( Couto, RA; Greene, AK, 2011)
"Prior to propranolol the systemic treatment for haemangiomas was prednisolone and then the concern was the opposite, namely hypertension."	5.42	Propranolol and prednisolone combination for the treatment of segmental haemangioma in PHACES syndrome. ( Batul Syed, S; Gnarra, M; Harper, J; Solman, L, 2015)
" A cavernous hemangioma was suspected and treated with high doses of propranolol and prednisolone."	3.85	Unexpected Effect of Propranolol and Prednisolone on Infantile Facial Rhabdomyosarcoma. ( Bhandari, SB; Lemperle, G; Mentzel, T; Shakya, J; Shilpakar, R, 2017)
"The study comprised 25 consecutive patients with infantile hemangioma managed with oral prednisolone between 2007 and 2010."	3.77	Oral prednisolone for infantile hemangioma: efficacy and safety using a standardized treatment protocol. ( Couto, RA; Greene, AK, 2011)
"Prior to propranolol the systemic treatment for haemangiomas was prednisolone and then the concern was the opposite, namely hypertension."	1.42	Propranolol and prednisolone combination for the treatment of segmental haemangioma in PHACES syndrome. ( Batul Syed, S; Gnarra, M; Harper, J; Solman, L, 2015)
"Sinus pericranii is a rare finding that has not, to our knowledge, been previously associated with PHACE syndrome."	1.33	Infantile midline facial hemangioma with agenesis of the corpus callosum and sinus pericranii: another face of the PHACE syndrome. ( Benjamin, L; Drosou, A; Linfante, I; Mallin, K; Schachner, LA; Thaller, SR; Trowers, A; Wakhloo, AK, 2006)
"After 11 months of treatment, the hemangioma had all but disappeared and interferon therapy was stopped."	1.31	[Effectiveness and dangers of interferon-alpha in the treatment of severe hemangiomas in infants]. ( Duveau, E; Enjolras, O; Giniès, JL; Grimal, I; Verret, JL, 2000)

Research

Studies (23)

Authors

Clinical Trials (10)

Trial Overview

Trial Outcomes

Interim Analysis : Complete/Nearly Complete Resolution of the Target Infantile Hemangioma at Week 24 Compared to Baseline Based on the Intra-patient Blinded Centralized Independent Qualitative Assessments of Week 24 Photographs.

Primary Analysis : Complete/Nearly Complete Resolution of the Target Infantile Hemangioma at W24 Compared to Baseline Based on the Intra-patient Blinded Centralized Independent Qualitative Assessments of W24 Photographs.

Allergy/Immunology Adverse Events

Timeframe	Studies, this research(%)	All Research%
pre-1990	3 (13.04)	18.7374
1990's	3 (13.04)	18.2507
2000's	9 (39.13)	29.6817
2010's	7 (30.43)	24.3611
2020's	1 (4.35)	2.80

Authors	Studies
Ogawa-Momohara, M	1
Muro, Y	1
Goto, K	1
Obuse, C	1
Satoh, M	1
Kono, M	1
Akiyama, M	1
Shilpakar, R	1
Lemperle, G	1
Mentzel, T	1
Shakya, J	1
Bhandari, SB	1
Gnarra, M	1
Solman, L	1
Harper, J	2
Batul Syed, S	1
Léauté-Labrèze, C	1
Dumas de la Roque, E	1
Hubiche, T	1
Boralevi, F	1
Thambo, JB	1
Taïeb, A	1
Ito, T	1
Yamamoto, T	1
Matsumoto, Y	1
Wakamatsu, J	1
Kato, Y	1
Tsuboi, R	1
Ommen, LB	1
Helgestad, J	1
Gammelgaard, L	1
Maguiness, SM	1
Frieden, IJ	1
Williams, JV	1
Revington, PJ	1
Greene, AK	1
Couto, RA	1
Chim, H	1
Gosain, AK	1
Blei, F	1
Douri, T	1
Ioannidis, AS	1
Liasis, A	1
Syed, S	1
Nischal, KK	1
Drosou, A	1
Benjamin, L	1
Linfante, I	1
Mallin, K	1
Trowers, A	1
Wakhloo, AK	1
Thaller, SR	1
Schachner, LA	1
Judd, CD	1
Chapman, PR	1
Koch, B	1
Shea, CJ	1
Maronn, ML	1
Corden, T	1
Drolet, BA	1
Edgerton, MT	1
Zav'ialov, PV	1
Gasanov, DG	1
Thomas, DW	1
Lewis, MA	1
Cowpe, JG	1
Kulkarni, ML	1
Kumar, CS	1
George, VG	1
Farooq, K	1
Onizuka, T	1
Satou, S	1
Koike, M	1
Ishiyama, T	1
Tomoyasu, S	1
Tsuruoka, N	1
Ohta, H	1
Fujisawa, R	1
Yamaguchi, A	1
Tashiro, T	1
Grimal, I	1
Duveau, E	1
Enjolras, O	1
Verret, JL	1
Giniès, JL	1
Ravitch, MM	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Propanolol Effect on Red Cell Adhesion in Non-Asthmatic Children With Sickle Cell Disease: A Dose Finding Study[NCT02012777]	Phase 1	9 participants (Actual)	Interventional	2010-06-30	Terminated (stopped due to Inability to recruit patients into the study.)
A Randomised, Controlled, Multidose, Multicentre, Adaptive Phase II/III Study in Infants With Proliferating Infantile Hemangiomas (IHs) Requiring Systemic Therapy to Compare 4 Regimens of Propranolol (1 or 3 mg/kg/Day for 3 or 6 Months) to Placebo (Double[NCT01056341]	Phase 2/Phase 3	512 participants (Actual)	Interventional	2010-01-31	Completed
Propranolol vs Prednisolone for Infant Hemangiomas-A Clinical and Molecular Study[NCT00967226]	Phase 2	19 participants (Actual)	Interventional	2009-07-31	Terminated (stopped due to Serious adverse events with prednisolone, primarily temporary growth retardation, <5th percentile.)
Melablock: A Multicentre Randomized, Double---blinded and Placebo---controlled Clinical Trial on the Efficacy and Safety of Once Daily Propranolol 80 mg Retard for the Prevention of Cutaneous Malignant Melanoma Recurrence[NCT02962947]	Phase 2/Phase 3	546 participants (Anticipated)	Interventional	2017-06-30	Not yet recruiting
"'' Efficacy of Propranolol in the Treatment of Infantile Hemangioma"[NCT04684667]	Phase 2	100 participants (Anticipated)	Interventional	2021-01-01	Not yet recruiting
Phase 2 Study of Sildenafil for the Treatment of Lymphatic Malformations[NCT02335242]	Phase 2	22 participants (Actual)	Interventional	2015-05-23	Completed
A Comparative Study of the Use of Beta Blocker and Oral Corticosteroid in the Treatment of Proliferative and Involuting Cutaneous Infantile Hemangioma[NCT01072045]	Phase 2	50 participants (Actual)	Interventional	2010-01-31	Completed
A Modular Open Label, Signal Seeking, Phase II Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations (TARGET-VM)[NCT05983159]	Phase 2	30 participants (Anticipated)	Interventional	2023-09-30	Not yet recruiting
Double Blind, Randomised, Placebo-controlled Study of Propranolol in Infantile Capillary Hemangiomas[NCT00744185]	Phase 2/Phase 3	14 participants (Actual)	Interventional	2008-10-31	Terminated (stopped due to Study halted prematurely due to some difficulties in recruitment of patients)
Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol[NCT01533376]	Phase 1	3 participants (Actual)	Interventional	2012-02-29	Terminated
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	percentage of participants (Number)
Placebo	8.0
Propranolol 1mg/kg/d 3 Months	9.8
Propranolol 1 mg/kg/d 6 Months	37.5
Propranolol 3 mg/kg/d 3 Months	7.7
Propranolol 3 mg/kg/d 6 Months	62.8

Intervention	percentage of participants (Number)
Placebo	3.6
Propranolol 3mg/kg/d 6 Months	60.4

Number of allergy/immunology AE per study arm (NCT00967226)
Timeframe: enrollment through study closeout or study withdrawal up to 9 months

Constitutional Adverse Events

Intervention	Adverse Events (Number)
Allergy/Immunology Events Propranolol	1
Allergy/Immunology Events Prednisolone	1

Number of constitutional AEs in each study arm. (NCT00967226)
Timeframe: enrollment to study close out or withdrawal up to 9 months

Decrease in Size of Hemangioma (Length x Width) in Square mm

Intervention	Adverse Events (Number)
Constitutional AEs Propranolol	2
Constitutional AEs Prednisolone	3

A priori primary outcome was proportional change in the total surface area as measured by lesion's outer margin length x width at baseline minus the same measure at 4 months with surrogate data used at 5 months if 4 months not available. (NCT00967226)
Timeframe: 4-5 months after initiating therapy

Dermatologic Adverse Events

Intervention	mm squared (Mean)
Propranolol	0.57
Prednisolone	0.63

Number of Dermatologic Adverse Events in each study arm. (NCT00967226)
Timeframe: enrollment to study close out or withdrawal up to 9 months

Endocrinologic Adverse Events

Intervention	Adverse Events (Number)
Dermatologic AEs Propranolol	2
Dermatologic AEs Prednisolone	1

Number of Endocrinologic AEs (of which adrenal crisis does not overlap). (NCT00967226)
Timeframe: enrollment to close out or study withdrawal up to 9 months

Gastrointestinal Adverse Events

Intervention	Adverse Events (Number)
Endocrine AEs Propranolol	0
Endocrinologic AEs Prednisolone	7

Number of Gastrointestinal AEs in each arm (NCT00967226)
Timeframe: enrollment to study withdrawal or study close out up to 9 months

Growth and Development Adverse Events

Intervention	Adverse Events (Number)
Gastrointestinal AEs Propranolol	6
Gastrointestinal AEs Prednisolone	6

Number of Growth and Development AEs in each study arm (NCT00967226)
Timeframe: enrollment to study withdrawal or close out up to 9 months

Infectious Adverse Events

Intervention	Adverse Events (Number)
Growth/Developoment AEs Propranolol	0
Growth/Development AEs Prednisolone	1

Number of infectious AEs in each study arm (i.e. conjunctivitis, thrush, fever) (NCT00967226)
Timeframe: enrollment to study withdrawal or close out up to 9 months

Metabolic or Laboratory AEs

Intervention	Adverse Events (Number)
Infectious AEs Propranolol	5
Infectious AEs Prednisolone	3

Number of Metabolic or Laboratory AEs in each study arm. (NCT00967226)
Timeframe: enrollment to study withdrawal or close out up to 9 months

Number of Serious Adverse Events (SAEs)

Intervention	Adverse Events (Number)
Metabolic/Laboratory AEs Propranolol	1
Metabolic/Laboratory AEs Prednisolone	0

Number of serious adverse events experienced by the participants in each treatment arm within the categories adrenal crisis, growth/development, constitutional. Serious adverse events are defined as events that result in death, require either inpatient hospitalization or the prolongation of hospitalization, are life-threatening, result in a persistent or significant disability/incapacity, or result in a congenital anomaly/birth defect. Other important medical events, based upon appropriate medical judgment, may also be considered Serious Adverse Events if a trial participant's health is at risk and intervention is required to prevent an outcome mentioned. (NCT00967226)
Timeframe: enrollment until study close out or withdrawal up to 9 months

Pulmonary/Respiratory Adverse Events

Intervention	Serious Adverse Events (Number)
Number of Serious Adverse Events in Propranolol	1
Number of Serious Adverse Events in Prednisolone	11

Number of pulmonary/respiratory adverse events (CTCAE 22) in each study arm (NCT00967226)
Timeframe: enrollment through study close out or withdrawal, up to 9 months

Vascular Adverse Events

Intervention	Adverse Events (Number)
Pulmonary/Respiratory AEs Propranolol	14
Pulmonary/Respiratory AEs Prednisolone	4

Number of Vascular AEs in each study arm. (NCT00967226)
Timeframe: enrollment to study withdrawal or close out up to 9 months

Tolerability of Medication

Intervention	Adverse Events (Number)
Vascular AEs Propranolol	3
Vascular AEs Prednisolone	4

All adverse events relating to medication tolerability including: adrenal crisis, growth/development, constitutional (dehydration), allergy/immunology, dermatologic, endocrine, GI, infection, metabolism/labs, pulmonary, vascular. (NCT00967226)
Timeframe: enrollment until study close out or withdrawal up to 9 months

Change in Lesion Volume of the Test Medication as Evaluated by MRI Examination.

Intervention	Events (Number)
	Adverse Events	Serious Adverse Events
Overall Number of Adverse Events in Prednisolone	30	11
Overall Number of Adverse Events in Propranolol	34	1

Participants will be followed for the duration of the study, an expected average of 20 weeks. (NCT02335242)
Timeframe: Baseline, week 20

Change in Subject's Assessment of Change in Lymphatic Malformation Overall Score

Intervention	percentage of volume (Mean)
Double-Blind Placebo	5.89
Open-Label Sildenafil	-8.54
Double-blind Sildenafil	-0.642

"Subject's evaluation of the overall change in lymphatic malformation. Participants will be followed from baseline to 20 weeks.~Patients rated change as no improvement, minimal improvement (1-25% change), fair improvement (25-50% change), good improvement (50-75% change), and excellent improvement (75-100% change)." (NCT02335242)
Timeframe: Baseline, week 20

Intervention	Participants (Count of Participants)
	No improvement	Minimal improvement	Fair improvement	Good improvement	Excellent improvement
Double-Blind Placebo	1	2	0	2	0
Double-Blind Sildenafil	2	4	1	1	0

Article	Year
Subacute cutaneous lupus erythematosus with melanocyte elimination induced by pembrolizumab. The Journal of dermatology, 2020, Volume: 47, Issue:6 Topics: Aged, 80 and over; Antibodies, Monoclonal, Humanized; Autoantibodies; Autoantigens; Facial Neoplasms	2020
Unexpected Effect of Propranolol and Prednisolone on Infantile Facial Rhabdomyosarcoma. Journal of pediatric hematology/oncology, 2017, Volume: 39, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Diagnosis, Differential; Facial Neoplasms; F	2017
Propranolol and prednisolone combination for the treatment of segmental haemangioma in PHACES syndrome. The British journal of dermatology, 2015, Volume: 173, Issue:1 Topics: Abnormalities, Multiple; Adrenergic beta-Antagonists; Antineoplastic Agents, Hormonal; Blepharoptosi	2015
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Propranolol for severe hemangiomas of infancy. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Facial Neoplasms; Glucocorticoids; Hemangiom	2008
Folliculotropic mycosis fungoides and a leonine clinical appearance of the face. Dermatology online journal, 2008, Sep-15, Volume: 14, Issue:9 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arm; Cyclophosphamide; Doxorubicin; Etoposide;	2008
[Infantile haemangioma and intracranial vascular malformation]. Ugeskrift for laeger, 2009, Sep-14, Volume: 171, Issue:38 Topics: Abnormalities, Multiple; Antineoplastic Agents, Hormonal; Carotid Artery, Internal; Eyelid Neoplasms	2009
Facial basal cell carcinoma in a young patient with Crohn disease. The Journal of craniofacial surgery, 2010, Volume: 21, Issue:6 Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Carcinoma, Basal Cell; Crohn Disease; Facial Neoplasm	2010
Oral prednisolone for infantile hemangioma: efficacy and safety using a standardized treatment protocol. Plastic and reconstructive surgery, 2011, Volume: 128, Issue:3 Topics: Administration, Oral; Anti-Inflammatory Agents; Dose-Response Relationship, Drug; Drug Administratio	2011
Discussion: Oral prednisolone for infantile hemangioma: efficacy and safety using a standardized treatment protocol. Plastic and reconstructive surgery, 2011, Volume: 128, Issue:3 Topics: Anti-Inflammatory Agents; Facial Neoplasms; Female; Head and Neck Neoplasms; Hemangioma; Humans; Mal	2011
Oral prednisolone for infantile hemangioma: efficacy and safety using a standardized treatment protocol. Plastic and reconstructive surgery, 2012, Volume: 129, Issue:5 Topics: Anti-Inflammatory Agents; Facial Neoplasms; Female; Head and Neck Neoplasms; Hemangioma; Humans; Mal	2012
Segmental facial hemangioma accompanied by brain anomalies: report of a case. Dermatology online journal, 2003, Volume: 9, Issue:5 Topics: Arachnoid Cysts; Cerebellum; Disease Progression; Facial Neoplasms; Fatal Outcome; Female; Hemangiom	2003
The value of visual evoked potentials in the evaluation of periorbital hemangiomas. American journal of ophthalmology, 2005, Volume: 140, Issue:2 Topics: Amblyopia; Astigmatism; Evoked Potentials, Visual; Eyelid Neoplasms; Facial Neoplasms; Female; Gluco	2005
Infantile midline facial hemangioma with agenesis of the corpus callosum and sinus pericranii: another face of the PHACE syndrome. Journal of the American Academy of Dermatology, 2006, Volume: 54, Issue:2 Topics: Abnormalities, Multiple; Agenesis of Corpus Callosum; Embolization, Therapeutic; Facial Neoplasms; F	2006
Intracranial infantile hemangiomas associated with PHACE syndrome. AJNR. American journal of neuroradiology, 2007, Volume: 28, Issue:1 Topics: Administration, Oral; Brain Neoplasms; Carotid Artery, Internal; Cerebellopontine Angle; Cerebellum;	2007
Pneumocystis carinii pneumonia in infant treated with oral steroids for hemangioma. Archives of dermatology, 2007, Volume: 143, Issue:9 Topics: Administration, Oral; Antineoplastic Agents, Hormonal; Facial Neoplasms; Female; Hemangioma; Humans;	2007
Vascular hamartomas and hemangiomas: classification and treatment. Southern medical journal, 1982, Volume: 75, Issue:12 Topics: Adolescent; Embolization, Therapeutic; Facial Neoplasms; Female; Hamartoma; Hemangioma; Humans; Infa	1982
[Treatment of hemangiomas in children]. Vestnik khirurgii imeni I. I. Grekova, 1980, Volume: 124, Issue:1 Topics: Child, Preschool; Facial Neoplasms; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Pre	1980
Cutaneous T-cell lymphoma presenting as facial swelling: report of a case and review of the literature. International journal of oral and maxillofacial surgery, 1994, Volume: 23, Issue:6 Pt 1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cheek; Cyclophosphamide; Etoposide; Facial Neo	1994
Oral steroids in the treatment of periorbital hemangioma. Indian pediatrics, 1993, Volume: 30, Issue:3 Topics: Facial Neoplasms; Hemangioma; Humans; Infant; Prednisolone	1993
[Parapsoriasis en plaque suspected of progression to mycosis fungoides associated with extranodal malignant B cell lymphoma of the cheek]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 1993, Volume: 34, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Cheek; Cyclophosphamide; Doxorubicin; Facial Neoplas	1993
[Effectiveness and dangers of interferon-alpha in the treatment of severe hemangiomas in infants]. Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2000, Volume: 7, Issue:2 Topics: Amblyopia; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Facial Neoplasms; Female; Follow-	2000
The nonoperative treatment of surgical conditions in children. Pediatrics, 1973, Volume: 51, Issue:3 Topics: Abdominal Muscles; Anti-Infective Agents, Local; Child; Child, Preschool; Congenital Abnormalities;	1973

prednisolone and Facial Neoplasms